Synthetic drugs may exceed the corresponding physiological agonists in selectivity

 Synthetic drugs may exceed the corresponding physiological agonists in selectivity

Angiotensin is an example of a peptide hormone. Peptide hormones and neurotransmitters are very numerous, and new ones are constantly being discovered, as are new loca-tions and receptors for known ones. While several drugs exist that act on peptide receptors (most notably, opioids), drug development generally lags behind the physiological characterization. The situation is quite different with an-other group of hormones / transmitters, which are small-er molecules, most of them related to amino acids. With many of these, the availability of drugs has enabled the characterization of different classes of receptors and their physiological roles. The classical example is the distinction ofα- and β-adrenergic receptors (which we will consider in more detail later on in this course). While both epinephrine and norepinephrine act on either receptor (though with somewhat different potency), the distinction became very clear with the synthetic analog isoproterenol, which acts very strongly on β-receptors but is virtually inactive on α-receptors (Figure 1.7).


Agonists and antagonists that are more selective than the physiological mediators are both theoretically interesting and of great practical importance. As a clinically signifi-cant example of a selective receptor antagonist, we may consider the H2 histamine receptor in the stomach, which is involved in the secretion of hydrochloric acid (Figure 1.8a). The mediator itself – histamine – was used as starting point in the search for analogs that would bind to the receptor but not activate it. The first derivative that displayed strongly reduced stimulatory activity (while still binding to the re-ceptor, of course) was N-guanylhistamine (Figure 1.8b). Further structural modification yielded cimetidine, which was the first clinically useful H 2 receptor blocker. It rep-resented a major improvement in ulcer therapy at the time and is still in use today, although more modern drugs have largely taken its place.


While H2-selective blockers retain some structural resem-blance to the original mediator (histamine), the same cannot be said of the likewise clinically useful H1 blockers, which were developed for the treatment of allergic diseases such as hay fever (Figure 1.9).

 

Indeed, the H1 blockers do seem to be plagued by signifi-cant `cross-talk' to receptors other than histamine receptors. This is not uncommon – many agents, particularly those that readily penetrate into the central nervous system, have incompletely defined receptor specificities, although they are usually given a label suggesting otherwise. They are frequently used regardless on a empirical basis, often for fairly diverse indications.

Comments

Post a Comment

Popular posts from this blog

Magnitude of Maternal Health problem in Ethiopia

  Magnitude of Maternal Health problem in Ethiopia   Maternal mortality is one of the health indicator which shows the burden of disease and death; the greatest differential between developing and developed countries. More than 150 million women become pregnant in developing countries each year and an estimated 500, 000 of them die from pregnancy related causes. Other than their health problems most women in the developing countries lack access to modern health care services and increase the magnitude of death from preventable problems. Lack of access to modern health care services has great impact on increasing maternal death. Most pregnant women do not receive antenatal care; deliver with out the assistance of trained health workers etc. The life time risk of death as a result of pregnancy or child birth is estimated at one in twenty – three for women in Africa, compared to about one in 10,000 for women in Northern Europe 75% of Maternal morbidity and mortality related to pregnancy a
Read more

Drug application and uptake - Pharmacokinetics

Image
  Drug application and uptake   You are certainly aware that drugs are applied by various routes; the choice depends largely on the pharmacokinetic properties of the drug in question. Table 2.1 lists some characteristics of the major routes.   We will look at the various routes of application in turn. Oral uptake is the most common one, so let's start with this one.   Oral drug application   Inside the digestive tract, drug molecules encounter a quite aggressive chemical milieu. E.g., the acidic pH in the stom-ach (pH ~2) and the presence of proteases and nucleases in the gut preclude the application of proteins, nucleic acids, and other labile molecules. The gut mucous membrane presents a barrier to uptake; many drugs are not able to ef-ficiently cross it by way of diffusion.   For those drugs that make it from the gut lumen into the blood, the liver presents another formidable barrier. All blood drained from the intestines (as well as the spleen and the pancreas) is first passed
Read more

Pharmacokinetics

  Pharmacokinetics   Whatever the actual mechanism of action of a drug may be, we will want to know: Does the drug actually reach its site of action, and for how long does it stay there? This is governed by three factors:   1.    Absorption: Uptake of the drug from the compartment of application into the blood   2.    Distribution: Transport / equilibration between the blood and the rest of the organism   3.    Elimination: Filtration and secretion in the kidneys; chemical modification in the liver   Broadly speaking, absorption and distribution determine the whether a drug will be available at its target site at all, while elimination determines for how long the drug effect will last. The issues of drug absorption, distribution and elimination are collectively referred to as `pharmacoki-netics'.
Read more